Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

In conclusion, our results suggest that high sCTLA-4 serum levels might predict favorable clinical outcome and higher risk of irAEs in IPI-treated MM patients. (Source: Cancer Immunology, Immunotherapy)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2yvdivR